

Expres<sup>2</sup>ion Biotech Holding AB  
Press Release, 2018-04-20

---

## Expres<sup>2</sup>ion's U.S. partner Integrated BioTherapeutics launches first Expres<sup>2</sup>-based research product

Expres<sup>2</sup>ion Biotech Holding AB's fully owned subsidiary Expres<sup>2</sup>ion Biotechnologies ApS ("Expres<sup>2</sup>ion") announces that its U.S.-based partner and licensee Integrated BioTherapeutics ("IBT") has initiated sales and marketing of its first Expres<sup>2</sup>-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT's high-quality research protein portfolio and can be used in the development of diagnostic or therapeutic products.

Expres<sup>2</sup>ion stated in July 2017 that the Company will receive a two-digit percentage royalty based on net sales of Expres<sup>2</sup>-based products that IBT will develop and sell to its clients. It was also stated that IBT is planning to launch approximately five products for research purposes annually, and that the collaboration is expected to generate annual revenues of up to 1 MSEK to Expres<sup>2</sup>ion, when fully implemented. The launch of this first product is in line with these estimates.

*"I am very pleased that the first commercial reagent produced using Expres<sup>2</sup> under the agreement with IBT is now on the market. This is the first of several planned products that will be marketed through partners, and we expect this new business area to represent both continued revenues as well as additional business opportunities", says Expres<sup>2</sup>ion's CEO Dr. Steen Klysner.*

The Ebola virus glycoprotein product can be ordered directly from IBT Bioservices' website, and there is also a catalogue data sheet available. Follow the links below to reach the website or the data sheet, respectively:

<http://www.ibtbioservices.com/>

[http://www.ibtbioservices.com/IBTBioServices/assets/File/datasheets/Cat0501-025Lot1711002\\_100ug.pdf](http://www.ibtbioservices.com/IBTBioServices/assets/File/datasheets/Cat0501-025Lot1711002_100ug.pdf)

### **About Integrated Biotherapeutics, Inc.**

Integrated BioTherapeutics, Inc., Rockville, Maryland, USA is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT's antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses, such as zika, ebola, dengue, Marburg, and others. IBT's service and reagent division doing business as IBT Bioservices ([www.ibtbioservices.com](http://www.ibtbioservices.com)) produces and markets high quality recombinant proteins and antibodies primarily for infectious disease research and offers in vitro and in vivo anti-microbial testing services.

### **Certified Adviser**

Sedermønt Fondkommission is appointed as Certified Adviser for Expres<sup>2</sup>ion.

### **For further information about Expres<sup>2</sup>ion Biotech Holding AB, please contact:**

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

*This press release contains information that Expres<sup>2</sup>ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on April 20, 2018.*

---

### **About Expres<sup>2</sup>ion**

Expres<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of Expres<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, Expres<sup>2</sup>, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, Expres<sup>2</sup>ion develops novel VLP based vaccines through the joint venture AdaptVac ApS that was founded in 2017.